References
- Duhig AM, Saha S, Smith S, et al. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. J Manag Care Spec Pharm. 2018;24(5):410–415. doi: 10.18553/jmcp.2017.16326
- Mahendraratnam N, Sorenson C, Richardson E, et al. Value-based arrangements may be more prevalent than assumed. Am J Manag Care. 2019;25:70–76. https://www.ajmc.com/view/valuebased-arrangements-may-be-more-prevalent-than-assumed
- Sachs R, Bagley N, Lakdawalla DN. Innovative contracting for pharmaceuticals and Medicaid’s best-price rule. J Health Polit Policy Law. 2018;43(1):5–18. doi: 10.1215/03616878-4249796
- FoCUS. Emerging market solutions for financing and reimbursement of durable cell and gene therapies. 2021 [cited 2023 Oct 18]; [p. 14 p.]. White Paper. Available from: https://newdigs.tuftsmedicalcenter.org/wp-content/uploads/2022/06/FoCUS-WP-CGT-Market-Solutions.pdf
- Cohen JP. Is there a future for value-based contracting? Value Health. 2020 Apr;23(4):416–417. doi: 10.1016/j.jval.2020.01.006
- Courtney MW, Barlow JF, Trusheim M Payer perspectives on reimbursement of one-time high-cost durable therapies [internet]. PharmExec.Com: Pharmaceutical Executive; 2020 [cited 2023 Oct 18]. Available from: https://www.pharmexec.com/view/payer-perspectives-reimbursement-one-time-high-cost-durable-therapies
- Barlow JF, Yang M, Teagarden JR. Are payers ready, willing, and able to provide access to new durable gene therapies? Value Health. 2019;22(6):642–647. doi: 10.1016/j.jval.2018.12.004
- FoCUS. Payer perspectives on financing and reimbursement of one-time high-cost durable treatments. 2019 [cited 2023 Oct 18]; p. 8. White paper. Available from: https://newdigs.tuftsmedicalcenter.org/wp-content/uploads/2019/10/MIT-FoCUS-Payer-Perspectives-2019F210v044.pdf
- Centers for Medicare & Medicaid Services (CMS). Value-based purchasing (VBP) arrangements for drug therapies using multiple best prices (release no. 116). 2022 [cited 2023 Oct 18]; p. 9. Technical guidance. Available from: https://www.medicaid.gov/prescription-drugs/downloads/mfr-rel-116-vbp.pdf
- Cavaller-Bellaubi M, Hughes-Wilson W, Kubinová Š, et al. Patients, payers and developers of orphan medicinal products: lessons learned from 10 years’ multi-stakeholder dialogue on improving access in Europe via MoCA. Orphanet J Rare Diseases. 2023;18(1):144. doi: 10.1186/s13023-023-02774-7